Bernhard Nocht Institute for Tropical Medicine

NeuroTrauma Sciences Announces Key Appointments to its Executive Leadership Team

Retrieved on: 
Wednesday, May 10, 2023
Harvard School of Dental Medicine, PPD, KU Leuven, Research and development, NTS, Medical Affairs Bureau, Pfizer, Senior, University of Brussels, Traumatic brain injury, Université Laval, Stroke, New product development, MBA, Thermo Fisher Scientific, CMO, Concordia University, Harvard T.H. Chan School of Public Health, CNS, DSM-IV codes, Bachelor of Science, Central nervous system, Eisai, Public health, Doctor of Science, MD, Columbia Business School, Tropical medicine, Master of Science, Bernhard Nocht Institute for Tropical Medicine, Quality assurance, Growth, Shirin David, Merck, Regulatory affairs, Biostatistics, MPH, VC, Epidemiology, Imperial College London, Injury, Management, Pharmaceutical industry, Neuroscience

Dr. de Somer brings more than 30 years of leadership in the biopharmaceutical industry to the NTS management team in his role as Chief Medical Officer.

Key Points: 
  • Dr. de Somer brings more than 30 years of leadership in the biopharmaceutical industry to the NTS management team in his role as Chief Medical Officer.
  • He held clinical development leadership responsibilities in Europe, the UK, and the US at Sandoz/Novartis Pharmaceuticals.
  • "We are pleased to welcome these industry veterans to our leadership team," said Carl Long, Chief Executive Officer.
  • We will value their leadership and direction as we advance NTS-104 through the clinic."

Galapagos publishes 2021 annual report and announces extraordinary and annual shareholders’ meetings

Retrieved on: 
Thursday, March 24, 2022
Diepenbeek, SEC, CSO, CEO, MD, Time, Fibrosis, Company, University, Proxy, Association, Dermatology, Health, Institute, Policy, Pharmacy, Rale, Medicine, Rheumatology, Letter, NASDAQ, Société Nationale de Crédit et d'Investissement, Solar Total Energy Project, Remuneration, Annual report, CFO, Government, Review, Bernhard Nocht Institute for Tropical Medicine, Inflammation, PDF, Gettysburg College, Patient, Total, Exercise, CET, University of Antwerp, Euronext, Retirement, Infection, Tropical medicine, Valeo, Immunology, COVID-19, VP, HIV, Galapagos NV, Ustekinumab, Executive Committee, Acquisition, Johnson & Johnson, Commission Supérieure des Comptes, Medical device, Management, Pharmaceutical industry, Janssen, Galápagos Islands, Infliximab, Veolia, Biology, ENSAE, Sanofi, Virco

Mechelen, Belgium; 24 March 2022, 21.01 CET; regulated information Galapagos NV (Euronext & NASDAQ: GLPG) published its annual report for the financial year 2021 and announces extraordinary and annual shareholders meetings to be held sequentially on Tuesday 26 April 2022 at 1:00 p.m. (CET) and 2:00 p.m. (CET), respectively, at the registered office of the Company.

Key Points: 
  • Mechelen, Belgium; 24 March 2022, 21.01 CET; regulated information Galapagos NV (Euronext & NASDAQ: GLPG) published its annual report for the financial year 2021 and announces extraordinary and annual shareholders meetings to be held sequentially on Tuesday 26 April 2022 at 1:00 p.m. (CET) and 2:00 p.m. (CET), respectively, at the registered office of the Company.
  • The annual report for the financial year 2021, including a review of figures and performance, is available online at https://www.glpg.com/financial-reports and can also be downloaded as PDF.
  • The convening notice and other documents pertaining to the shareholders meetings can be consulted on our website, www.glpg.com/shareholders-meetings .
  • We are monitoring the situation closely and will, if necessary, disclose additional relevant information and measures affecting the shareholders meetings on the Galapagos website ( https://www.glpg.com/shareholders-meetings ).

HMNC Brain Health Appoints Dr. Bertram Müller-Myhsok as Head of Precision Psychiatry

Retrieved on: 
Thursday, February 24, 2022
University, GLOBE, Genetics, Department of Medicine – University of Pamplona, Faculty, Disorder, Head, MDD, LION, Statistical genetics, Bernhard Nocht Institute for Tropical Medicine, Tropical medicine, Habilitation, Max Planck Institute of Psychiatry, Industry, Company, Psychiatry, Ludwig Maximilian University of Munich, Lists of diseases, United Kingdom, Genetic testing, Technical University of Munich, Institute of technology, Human genetics, List of life sciences, Professor, Non-functional testing, VC, Senior, Artificial intelligence, Annemarie, Brain, TRD, Patient, Pontifical Xavierian University Faculty of Medicine, Knowledge, Research, Program, Department, Pharmaceutical industry, Medicine

MUNICH, Germany, Feb. 24, 2022 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC'' or the “Company”), a clinical stage biopharmaceutical company pioneering the development of personalized therapies in psychiatry, announced today the appointment of Dr. Bertram Müller-Myhsok as its new Head of Precision Psychiatry, effective March 1, 2022. The Head of the Statistical Genetics Research Group at Max-Planck-Institute of Psychiatry in Munich has signed an additional contract with HMNC Brain Health next to his position at the Max-Planck-Institute. In his new role, Dr. Müller-Myhsok will help the Company to accelerate the development of differentiated treatment options through the combination of novel interventions with precision applications.

Key Points: 
  • MUNICH, Germany, Feb. 24, 2022 (GLOBE NEWSWIRE) -- HMNC Brain Health (HMNC'' or the Company), a clinical stage biopharmaceutical company pioneering the development of personalized therapies in psychiatry, announced today the appointment of Dr. Bertram Mller-Myhsok as its new Head of Precision Psychiatry, effective March 1, 2022.
  • The Head of the Statistical Genetics Research Group at Max-Planck-Institute of Psychiatry in Munich has signed an additional contract with HMNC Brain Health next to his position at the Max-Planck-Institute.
  • As Head of Precision Psychiatry, Dr. Mller-Myhsoks decades of experience in human genetics research will allow HMNC Brain Health to advance its work utilizing genetic analyses and artificial intelligence to better detect the underlying genetic or physiological causes of disorders in specific individuals and develop personalized therapies for neuropsychiatric disorders.
  • HMNC Brain Health (HMNC Holding GmbH) is a global precision psychiatry biopharma company pioneering the development of personalized therapies powered by predictive companion diagnostics, leading to far shorter treatments and higher remission rates.

Galapagos appoints Paul Stoffels as Chief Executive Officer

Retrieved on: 
Wednesday, January 26, 2022
Tropical medicine, Diepenbeek, Institute, University of Antwerp, Gilead, Infection, COVID-19, Janssen Vaccines, J&J, Research, Medicine, Bernhard Nocht Institute for Tropical Medicine, University, S-1 Executive Committee, Leadership, Inflammation, NASDAQ, Executive Committee, Industry, Galapagos NV, CET, Patient, Fibrosis, Euronext, Retirement, Acquisition, CEO, Management, Fine chemical, Pharmaceutical industry, Virco, Tibotec, Galápagos Islands

Succeeds current Chief Executive Officer and co-founder Onno van de Stolpe, following planned retirement

Key Points: 
  • Succeeds current Chief Executive Officer and co-founder Onno van de Stolpe, following planned retirement
    Recognized as inspirational industry leader with exceptional R&D as well as global executive experience, and a strong focus on bringing innovative medicines to patients
    Mechelen, Belgium; 26 January 2022, 22.01 CET; regulated information Galapagos NV (Euronext & NASDAQ: GLPG) is pleased to announce the appointment of Dr. Paul Stoffels as Chief Executive Officer (CEO), effective April 1, 2022.
  • After a rigorous selection process, we are very pleased to announce Paul as our next CEO.
  • Given his extraordinary R&D as well as managerial experience, extensive network, along with his deep understanding of Galapagos strengths and potential, we are convinced that Paul is uniquely qualified to lead Galapagos, said Dr. Raj Parekh, Chairman of Galapagos.
  • After a transition period during which Onno will hand over his activities, Paul Stoffels* will fully take over as CEO effective April 1, 2022.

Fab’entech, Winner in an Ambitious European Programme, Has Been Awarded 9.2 Million Euros to Develop Its Treatment against Covid-19 and its Variants

Retrieved on: 
Monday, December 13, 2021
Biotechnology, Other Health, Health, State, Local, Pharmaceutical, Other Science, Infectious Diseases, Hospitals, Public Policy, Government, Science, Clinical Trials, Teaching hospital, IRD, Hellenic Institute of Byzantine and Post-Byzantine Studies in Venice, Tropical medicine, Severe acute respiratory syndrome coronavirus 2, Population, Clinician Administered PTSD Scale, Biomarker, Bernhard Nocht Institute for Tropical Medicine, European Commission, Time, United Nations Research Institute for Social Development, Sanofi Pasteur, HERA, CEO, Research, Antigen presentation, Patient, Disease, Infection, COVID-19, WHO, Mutation, Sustainable development, Royal commission, Antibody, Breathe Me, Heart, Pharmaceutical industry, Vaccine, Sepsis

The EPIC-CROWN-2 project, initiated by Fabentech (Lyon-based biotech company), has received funding to the tune of 9.2 million euros from the European Commission.

Key Points: 
  • The EPIC-CROWN-2 project, initiated by Fabentech (Lyon-based biotech company), has received funding to the tune of 9.2 million euros from the European Commission.
  • With global funding of 9.2 million euros, the consortium is one of the 11 European projects selected.
  • Targeting the treatment of at-risk patients with moderate to severe symptoms of respiratory distress, it has provided the preclinical demonstration of its efficacy against the main variants currently circulating.
  • We are proud and happy to be one of the winners in the first call for HERA projects.